IP Library Granted Patent US 11,103,583
Granted Patent B2
US 11,103,583 · App. 16/460,812 · Granted Aug 31, 2021

Lipids for therapeutic agent delivery formulations

Inventors: Joseph E. Payne (Oceanside, CA); John A. Gaudette (Poway, CA); Zheng Hou (San Diego, CA); Mohammad Ahmadian (Carlsbad, CA); Lei Yu (Carlsbad, CA); Victor Knopov (Oceanside, CA); Violetta Akopian (Oceanside, CA); Priya Karmali (San Diego, CA); Richard P. Witte (San Diego, CA); Neda Safarzadeh (Poway, CA); Wenbin Ying (San Diego, CA); Jun Zhang (San Diego, CA)
Assignee: Nitto Denko Corporation
A61K47/20A61K9/1272A61K47/14A61K47/18A61K47/22C07C235/08C07C237/08C07C237/16C07C271/16C07C317/44C07C323/60C07C333/04C07D207/16C07D333/38C07D333/40Y10T428/2998
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,103,583
App. No.
16/460,812
Granted
Aug 31, 2021
Kind
B2
Abstract

The description is directed to ionizable lipids useful for enhancing the delivery of therapeutic agents in liposomes.

Claims (24)

1. A compound of formula I:

wherein

n and m are independently 1, 2, 3, or 4;

R 1 and R 2 are independently C 10-18 alkyl- or C 12-18 alkenyl-;

X is —CH 2 —, and L is —OC(O)C 1-4 alkylene-; or

X is absent, and L is —OC 1-4 alkylene- or —OC(O)C 1-4 alkylene-; or

X is O or N, and L is —C 1-4 alkylene-;

or a pharmaceutically acceptable salt form thereof.

2. The compound of claim 1 , wherein n and m are independently 1 or 2.

3. The compound of claim 2 , wherein X is absent.

4. The compound of claim 3 , wherein L is —OC 1-4 alkylene- or —OC(O)C 1-4 alkylene-.

5. The compound of claim 1 , wherein X is —CH 2 —.

6. The compound of claim 5 , wherein L is —OC(O)CH 2 CH 2 CH 2 —.

7. The compound of claim 2 , wherein X is O.

8. The compound of claim 2 , wherein R 1 and R 2 are each C 10-18 alkyl-.

9. The compound of claim 2 , wherein R 1 and R 2 are each C 13 alkyl-.

10. A pharmaceutical composition comprising the compound of claim 1 .

11. The pharmaceutical composition of claim 10 comprising a therapeutically effective amount of RNA.

12. A compound selected from the group consisting of

13. A pharmaceutical composition comprising the compound of claim 12 .

14. The pharmaceutical composition of claim 13 comprising a therapeutically effective amount of RNA.

15. A compound selected from the group consisting of

16. A pharmaceutical composition comprising the compound of claim 15 .

17. The pharmaceutical composition of claim 16 comprising a therapeutically effective amount of RNA.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 26, 2021
From: PAYNE, JOSEPH E.; GAUDETTE, JOHN A.; HOU, ZHENG; AHMADIAN, MOHAMMAD; KNOPOV, VICTOR; AKOPIAN, VIOLETTA; KARMALI, PRIYA; WITTE, RICHARD P.; SAFARZADEH, NEDA; YING, WENBIN; ZHANG, JUN
To: NITTO DENKO CORPORATION
Reel/Frame 056107/0452 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2019
From: YU, LEI
To: NITTO DENKO CORPORATION
Reel/Frame 050946/0264 →
Continuity (4)
Continuation 14872951 · Oct 1, 2015
Division 13913918 · Jun 10, 2013
Provisional Application 61657480 · Jun 8, 2012
Related Publication 20200085957A1 · Mar 19, 2020